Forsta AP Fonden Has $3.01 Million Position in DaVita Inc. (NYSE:DVA)

Forsta AP Fonden lessened its position in DaVita Inc. (NYSE:DVA) by 42.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 20,100 shares of the company’s stock after selling 14,900 shares during the period. Forsta AP Fonden’s holdings in DaVita were worth $3,006,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. The Manufacturers Life Insurance Company increased its stake in DaVita by 0.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,244 shares of the company’s stock valued at $6,269,000 after purchasing an additional 150 shares in the last quarter. Creative Planning grew its holdings in shares of DaVita by 5.0% during the second quarter. Creative Planning now owns 8,297 shares of the company’s stock valued at $1,150,000 after buying an additional 394 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of DaVita by 78.9% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 4,130 shares of the company’s stock worth $572,000 after acquiring an additional 1,822 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in DaVita in the 2nd quarter valued at about $2,314,000. Finally, Handelsbanken Fonder AB boosted its stake in DaVita by 13.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,900 shares of the company’s stock valued at $2,279,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

DVA stock opened at $176.16 on Friday. The business has a 50 day moving average of $159.72 and a 200-day moving average of $155.17. The firm has a market cap of $14.44 billion, a PE ratio of 19.00, a P/E/G ratio of 0.85 and a beta of 0.92. DaVita Inc. has a 12-month low of $107.74 and a 12-month high of $179.60. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent research reports. Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays raised their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.